ARIAD Pharmaceuticals, Inc.
ARIAD Announces Start of Phase 2 Clinical Trial of Oral Deforolimus in Patients with Metastatic, HER2-Positive Breast Cancer
Published in Cancer Weekly, August 12th, 2008
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) announced that it has initiated a Phase 2 clinical trial to examine the efficacy and safety of oral deforolimus, its investigational mTOR inhibitor, in patients with advanced breast cancer. In collaboration with Merck & Co. Inc., deforolimus is currently being evaluated in multiple clinical trials, both alone and in combination with other therapies, for the treatment of patients with several different cancer types. Under terms of the agreement, ARIAD will receive a $15 million milestone payment from Merck for treating the first patient in the breast cancer clinical trial.
The multi-center, single-arm, Phase 2 study will...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2008-08-12)
More Articles from Cancer Weekly
- Weber Shandwick Worldwide
Plasma DNA level is a reliable marker of recurrent esophageal cancer, study finds - Brain Cancer
Drugs Commonly Used for Erectile Dysfunction Allowed More Chemotherapy to Reach Brain Tumors in Laboratory Animal Study - Cancer Gene Therapy
New cancer gene therapy research from F. Wang and co-researchers described - Cancer Gene Therapy
Research from Chiba University yields new findings on cancer gene therapy - Cancer Gene Therapy
Studies from Nankai University have provided new data on cancer gene therapy - Cancer Gene Therapy
Studies from S. Loiselmeyer et al further understanding of cancer gene therapy - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
